Targeted Cancer Therapy

Overview

Targeted cancer therapy refers to a class of anticancer treatments designed to interfere with specific molecules, signaling pathways, or cellular processes that are critical for tumor growth, survival, invasion, or resistance. In contrast to conventional cytotoxic chemotherapy, which broadly affects rapidly dividing cells, targeted therapy aims for greater selectivity by acting on defined molecular vulnerabilities such as receptor tyrosine kinases, cell-cycle regulators, DNA repair pathways, tumor microenvironment components, or survival signaling networks. In recent oncology literature, targeted therapy is frequently discussed alongside immunotherapy, chemotherapy, and radiation therapy as part of precision treatment strategies.

Biologically, targeted cancer therapy is closely linked to tumor heterogeneity and the need to match treatment to actionable alterations. It is often guided by biomarkers derived from multi-omics data, liquid biopsy, clinomics, or computational tools, and it may be combined with agents such as cisplatin, gemcitabine, or checkpoint inhibitor. Recent studies also emphasize resistance mechanisms involving ferroptosis, Intracellular ROS, mitochondrion-related pathways, PD-1/PD-L1 signaling, VEGFA, mTOR, CD44, and Erb-b2 receptor tyrosine kinase 2, underscoring that targeted therapy is both a treatment strategy and a major research framework in precision oncology.

Focus of Latest Publications

Recent publications portray targeted cancer therapy as a central component of modern oncology across multiple tumor types, with a strong emphasis on precision medicine, resistance biology, and combination treatment strategies.

A 2026 review in Critical Reviews in Oncology/Hematology described targeted cancer therapy as having fundamentally reshaped oncology by moving beyond broad cytotoxicity toward selective interference with molecules or pathways essential for cancer cell survival and proliferation. This framing reflects the broader research trend seen across the cited studies: targeted therapy is increasingly integrated with immunotherapy, chemotherapy, and multidisciplinary treatment rather than used as a standalone approach.

Several studies focused on the use of targeted therapy in specific cancers and clinical settings. In metastatic melanoma, a multi-modal computational analysis highlighted that immunotherapy and targeted therapy have significantly improved survival, while also noting that treatment failure and resistance remain major challenges. In prostate cancer, a clinical study examined the benefit and safety of combining immunotherapy with targeted therapies, concluding that this combined approach has emerged as a promising way to enhance immune responses. In advanced biliary tract cancer, a review summarized recent progress in immunotherapy and targeted therapy, emphasizing pivotal clinical trials, therapeutic efficacy, current limitations, and future directions for personalized treatment strategies.

Targeted therapy was also discussed in disease-specific reviews and translational studies. In esophageal cancer, a precision-therapy review summarized progress in chemotherapy, targeted therapy, immunotherapy, and multidisciplinary treatment. In thymic epithelial tumors, a rare-tumor review addressed the evolving role of immunotherapy and targeted therapy while noting challenges such as autoimmune disease recurrence and adverse events. In head and neck cancer, a study on RNF149 noted that although surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy are available, disease control remains limited. In hepatic neuroendocrine tumors, a case-based review stated that late-stage management often requires combining local treatments with systemic therapies such as peptide receptor radionuclide therapy, chemotherapy, and targeted therapy.

Mechanism-oriented studies linked targeted therapy to specific molecular vulnerabilities. In PRCC-TFE3 driven renal cell carcinoma, investigators identified the Cyclin C-CDK8/19 Mediator kinase module as a mechanistic and therapeutic vulnerability, providing a rationale for mechanism-based targeted therapy. In urothelial cancer, a study of CD44 and STAT3 aimed to improve understanding of targeted therapy by defining shared and distinct roles of these molecules in spheroid viability and pembrolizumab response. In lung adenocarcinoma, single-cell RNA sequencing and machine learning were used to identify prognostic genes and immune cell signatures, with the authors stating that the work provided novel ideas for improving prognosis and developing targeted therapy. In gastrointestinal tumor biology, an OMICS-focused review suggested that targeted therapy will broaden the clinical landscape by enabling development of therapeutics against new vulnerable targets.

Resistance to targeted therapy was a recurring theme. In gastric cancer, spatial multi-omics was used to unravel multidimensional mechanisms of resistance to chemotherapy, targeted therapy, and immunotherapy. In human malignancies more broadly, HMGB3 was described as a pivotal orchestrator of therapy resistance and cancer stemness, contributing to resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy collectively. In pancreatic adenocarcinoma, a machine learning-based prognostic signature integrating mitochondrial function and programmed cell death patterns suggested that high-risk patients derived more benefit from immunotherapy but less from chemotherapy and targeted therapy. In melanoma quality-of-life research, new treatments such as targeted therapy and immunotherapy were noted to have unique adverse events compared with surgery and chemotherapy, reflecting the clinical importance of toxicity profiling alongside efficacy.

Targeted therapy was also explored in translational and nanomedicine contexts. A hepatocellular carcinoma study described a hyaluronic acid-targeted copper/manganese nanobioreactor with H2O2 self-supply that induced ferroptosis and apoptosis, presenting it as a promising strategy for targeted cancer therapy. This aligns with broader work on nanoparticle delivery systems, nucleic acid delivery technologies, and hyaluronan-modified Mn-based complexes, which aim to improve tumor selectivity and intracellular delivery. Related mechanistic studies referenced Fenton-like reactions, hydrogen peroxide, GSH levels, and Intracellular ROS, indicating that redox-based nanotherapeutics are being developed as targeted approaches to kill cancer cells while exploiting tumor-specific oxidative stress vulnerabilities.

Across tumor types, targeted therapy is repeatedly positioned as part of combination regimens. Studies in melanoma, prostate cancer, biliary tract cancer, lung cancer, esophageal cancer, thymic epithelial tumors, and hepatic neuroendocrine tumors all emphasized integration with immunotherapy, chemotherapy, radiation therapy, or local interventions. The recurring mention of pembrolizumab, PD-1/PD-L1, tumor microenvironment, VEGFA, and Erb-b2 receptor tyrosine kinase 2 reflects the molecular and immunologic pathways most often considered in contemporary targeted treatment strategies.

Key Publications

• Jun Hyaluronic acid-targeted copper/manganese nanobioreactor with H2O2 self-supply for simultaneous induction of ferroptosis and apoptosis in hepatocellular carcinoma. (International journal of biological macromolecules, 2026, PMID 42097419): "offering a promising strategy for targeted cancer therapy."
• May Pearls & Oy-sters: Stroke Recurrence After PFO Closure Uncovers Cerebrotendinous Xanthomatosis. (Neurology, 2026, PMID 42102332): "Early recognition enables targeted therapy and improves outcomes."
• May Machine learning-based prognostic signature integrating mitochondrial function and programmed cell death patterns in pancreatic adenocarcinoma. (Scientific reports, 2026, PMID 42098410): "Drug sensitivity analysis indicated the high-risk group derived more benefits from immunotherapy but less from chemotherapy and targeted therapy."
• May Myelin oligodendrocyte glycoprotein antibody-associated disease after transforaminal lumbar interbody fusion surgery: a case report. (Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026, PMID 42098373): "The patient subsequently received targeted therapy and recovered well."
• May Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanoma. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41895000): "Novel therapies like immunotherapy (ICI) and targeted therapy (TT) have significantly improved survival in metastatic melanoma, but treatment failure and/or development of treatment resistance pose major challenges."
• May The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC. (Neoplasia (New York, N.Y.), 2026, PMID 41843980): "These findings define the Mediator kinase module as a mechanistic and therapeutic vulnerability in PRCC-TFE3 driven TFE3-RCC, providing a rationale for mechanism based targeted therapy."
• May Ubiquitin Ligase RNF149 Promotes Head and Neck Cancer Growth via Downregulation of CDKN2C. (Anticancer research, 2026, PMID 42049330): "Although surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy are available, their success in controlling the disease remains limited."
• May New Pathological Insights into Biomarkers for Multimodal Therapeutic Approach in Hepatic Neuroendocrine Tumors: A Detailed Case Report. (In vivo (Athens, Greece), 2026, PMID 42049452): "Treatment for late-stage disease including combining local treatment (surgery, radiofrequency ablation, selective internal radiation therapy, trans-hepatic arterial chemo-embolization/trans-hepatic arterial embolization) with that for systemic disease, such as peptide receptor radionuclide therapy, chemotherapy and targeted therapy, are essential for managing symptoms and improving outcomes."
• May Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. (Anticancer research, 2026, PMID 42049372): "This study aimed to unveil the shared and distinct roles of STAT3 and CD44 and obtain a better understanding of targeted therapy in UC."
• May Integration of Single-Cell RNA Sequencing and Machine Learning to Identify and Validate Prognostic Genes With Lymph Node Metastasis and Immune Cell Signatures in Lung Adenocarcinoma. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 41979566): "...and provided novel ideas on how to improve poor prognosis and develop targeted therapy for LUAD."